Received Jul 31, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | — |
Inadvertent Administration of Only the Liquid Conjugate Component of the 2-vial Presentation of Menveo; Inappropriate dose of vaccine administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a 12-year-old patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On an unknown date, the patient received the 1st dose of Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: Inadvertent Administration of Only the Liquid Conjugate Component of the 2-vial Presentation of Menveo) and inappropriate dose of vaccine administered (Verbatim: Inappropriate dose of vaccine administered). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 21-JUL-2025 The reporter reported that the provider only gave the liquid part of the Menveo 2-part vaccine (1st dose in series for 12 year old) which led to inappropriate dose of vaccine administered and inappropriate preparation of medication. The lyophilized vial was not given. The reporter asked were there any recommendations for this situation. The reporter asked could the powder be given separately, and if so what should it be diluted with.